TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma
Phase 1
Terminated
- Conditions
- Multiple Myeloma
- Registration Number
- NCT00243763
- Lead Sponsor
- Novartis
- Brief Summary
The primary objective of this study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of CHIR-258 when administered to subjects with refractory or relapsed multiple myeloma (MM).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria
- Confirmed diagnosis of multiple myeloma
- Evidence of relapsed or refractory disease
Read More
Exclusion Criteria
- Intracranial disease or epidural disease
- Clinically significant cardiac disease
- Diabetes mellitus
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Maximum tolerated dose Dose limiting toxicity Safety profile
- Secondary Outcome Measures
Name Time Method Evaluation of pharmacokinetics and pharmacodynamics
Trial Locations
- Locations (5)
Emory University
🇺🇸Atlanta, Georgia, United States
Mayo Clinic - Arizona
🇺🇸Scottsdale, Arizona, United States
Dana-Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
H. Lee Moffitt Cancer Center and Research Institute
🇺🇸Tampa, Florida, United States
Mayo Clinic - Minnesota
🇺🇸Rochester, Minnesota, United States